Clinical Trial Update: A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies [Phase 1, Phase 2]

View source ↗

Summary

This is a Phase 1/2 dose-escalation and expansion study of BGB-16673 in patients with various B-cell malignancies and is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Diffuse Large B-cell Lymphoma
• Follicular Lymphoma
• Mantle Cell Lymphoma
• Marginal Zone Lymphoma
• Non-hodgkin Lymphoma
• Small Lymphocytic Lymphoma
• Waldenström Macroglobulinemia

Drugs mentioned

• BGB-16673

Snippet

Sponsor: BeOne Medicines | Conditions: B-cell Malignancy, Marginal Zone Lymphoma | Phase 1, Phase 2 | Status: RECRUITING